Adjuvant chemotherapy for colon cancer: A confusing area!

Annals of Oncology

Volumn 16, Issue 12, 2005, Pages 1853-1854

  Douillard, J Y ^a   Bennouna, J ^a  

^a CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

Aqueous; Ifosfamide; Intraocular lymphoma; Trofosfamide

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; THYMIDINE PHOSPHATE; THYMIDINE PHOSPHORYLASE; UFT;

BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DRUG COST; DRUG SAFETY; EDITORIAL; FOLLOW UP; HIGH RISK PATIENT; HUMAN; META ANALYSIS; METASTASIS; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; SYSTEMATIC REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; HUMANS; PROGNOSIS;

EID: 28444458488     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi413     Document Type: Editorial

References (13)

1. Moertel CG, Fleming TR, Macdonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-358.
2. André T, Colin P, Louvet C et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: Results of a randomized trial. J Clin Oncol 2003; 21: 2896-2903.
3. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704.
4. Wolmark N, Wieand S, Lembersky B, Colangelo L, Smith R, Pazdur R. A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: Results of NSABP Protocol C-06. J Clin Oncol 2004; 22 (July 15 Suppl): 3508.
5. André T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
6. de Gramont A, Boni C, Navarro M et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years. Proc Am Soc Clin Oncol 2005; 23: Abstr 3501.
7. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999; 17: 1356-1363.
8. Gray RG. QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. J Clin Oncol 2004; 22 (July 15 Suppl): 3501.
9. Wolmark N, Wieand HS, Kuebler JP, Colangelo L, Smith RE. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. Proc Am Soc Clin Oncol 2005; 23: Abstr 3500.
10. Saltz LB, Niedzwiecki D, Hollis D et al. Irinotecan plus fluorouracil/ leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). J Clin Oncol 2004; 22 (July 15 Suppl): 3500.
11. Ychou M, Raoul J, Douillard J et al. A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). Proc Am Soc Clin Oncol 2005; 23: Abstr 3502.
12. Van Cutsem E, Labianca R, Hossfeld D et al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). Proc Am Soc Clin Oncol 2005; 23: Abstr 8.
13. Sargent DJ, Wieand S, Benedetti J et al. Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials. J Clin Oncol 2004; 22 (July 15 Suppl): 3502.